1,233 results on '"Grossman, H. Barton"'
Search Results
2. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes
3. Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?
4. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign
5. Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
6. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer
7. Data from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
8. Perspective on This Article from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
9. Data from Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
10. Supplementary Figures S1-S3 from Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
11. Data from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
12. Supplementary Materials, Figures 1 - 3, Tables 1 - 4, 6 - 8 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
13. Supplementary Table 5 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
14. Clinical Outcomes of cT1 Micropapillary Bladder Cancer
15. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
16. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non–muscle invasive bladder cancer
17. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors
18. Fluorescence Cytoscopy
19. Bladder Cancer : Clinical Strategies for Cancer Chemoprevention
20. Reply by Authors
21. MP59-01 URINE MICRORNAS AS LIQUID BIOPSY ASSAY FOR PREDICTING RESPONSE TO INTRAVESICAL BCG THERAPY
22. Recent Developments in the Treatment of Bladder Cancer
23. Tumor Suppressor Genes of Bladder Cancer and Potential for Gene Therapy
24. The Use of Tumor Markers in Bladder Cancer and Current Concepts on Clinical Applicability
25. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer
26. Urothelial Differentiation and Bladder Cancer
27. Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy
28. Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial
29. Plasma Vitamins E and A and Risk of Bladder Cancer: A Case-Control Analysis
30. The role of radical cystectomy in patients with clinical T4b bladder cancer
31. Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy
32. Urinary Tract Diseases and Bladder Cancer Risk: A Case-Control Study
33. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer
34. BCAN Think Tank session 3: Prevention of bladder cancer
35. Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy
36. Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria
37. PD51-06 PROGRESSION AFTER BCG THERAPY: REFINING PATIENT SELECTION FOR NEOADJUVANT CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY
38. MP16-06 A NOVEL NOMOGRAM TO PREDICT BCG RESPONSE IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
39. PD63-04 ALL HIGH-GRADE NMIBC IS HIGH RISK: BCG RESPONSE IN HIGH-GRADE TA TUMORS
40. PD09-09 IMPLICATIONS OF GUIDELINE-BASED, RISK-STRATIFIED RESTAGING TRANSURETHRAL RESECTION OF HG TA UROTHELIAL CARCINOMA ON BCG THERAPY OUTCOMES
41. Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy
42. Cardiac History and Risk of Post-cystectomy Cardiac Complications
43. The Use of Short Tandem Repeat Profiling to Characterize Human Bladder Cancer Cell Lines
44. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
45. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design
46. Reply by Authors
47. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy
48. Forced COX-2 expression induces PGE 2 and invasion in immortalized urothelial cells
49. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms
50. Clinical Model of Cost of Bladder Cancer in the Elderly
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.